Adapt Pharma said today that the FDA approved the 2mg formulation of its Narcan nasal spray for the emergency treatment of opioid overdose.
The 2mg dose is intended for opioid-dependent patients that are at risk for severe withdrawal, but are not at a high risk for continued opioid exposure. The approval comes 1 year after the FDA approved its 4mg formulation, which was the 1st needle-free version of naloxone.
Get the full story at our sister site, Drug Delivery Business News.